Sangamo: In Vivo Editing of the Gene Behind Hunter Syndrome

Yes, it is Sangamo’s (SGMO) zinc finger nuclease (ZFN) gene-editing technology, which for the first time in history enabled a patient to receive a treatment to edit the DNA of his cells directly inside the body. That was the news coming today from Sangamo.
The Story
Sangamo’s gene editing product known as SB-913 -- an investigational in vivo genome editing therapy was introduced for the first time to the first patient in a Phase 1/2 CHAMPION clinical trial for people with mucopolysaccharidosis type II (MPS . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.